HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Google Scholar Articles by Shander, A. Articles by Javidroozi, M. PubMed Articles by Shander, A. Articles by Javidroozi, M. Related Collections Extracorporeal circulation Related Article

---

Original Articles: Cardiovascular

Invited Commentary

Anesthesiology and Critical Care Medicine, Englewood Hospital and Medical Center, 350 Engle St, Englewood, NJ 07631

(Email: aryeh.shander@ehmc.com; mazyarjr@yahoo.com).

Level 1 evidence is seriously lagging behind the wide off-label use of recombinant activated factor VII (rFVIIa) in the control of massive or insurmountable bleeding. Dunkley and colleagues [1] have made a commendable effort in gathering and analyzing the data on nonhemophilia cardiac surgery cases with critical bleeding treated with rFVIIa from a large multicenter registry with financial support from Novo Nordisk. The study faces limitations, many of which are shared with other registries; lack of a control group is perhaps the biggest obstacle in interpreting the data, given the complicated . . . [Full Text of this Article]

Related Article

Recombinant Activated Factor VII in Cardiac Surgery: Experience From the Australian and New Zealand Haemostasis Registry

Scott Dunkley, Louise Phillips, Peter McCall, John Brereton, Robert Lindeman, Gary Jankelowitz, and Peter Cameron
Ann. Thorac. Surg. 2008 85: 836-844. [Abstract] [Full Text] [PDF]